Tüdőrák: vizsgálatok itt: Portugália
43 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 17.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Where
- Braga, Loures, Porto, Vila Nova de Gaia
- Életkor
- 18 év and over
- People
- 282 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00 - 2/3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Braga, Porto
- Életkor
- 18 év and over
- People
- 854 worldwide
- Run by
- AbbVie
See details and how to joinNCT07005102 - 2/3. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Braga, Guimaraes, Loures, Porto, Senhora Da Hora
- Életkor
- 18 év and over
- People
- 490 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00 - 1. fázisTaking peopleA Study of ZW251 in Participants With Advanced Solid Tumors
- Where
- Lisbon, Vila Nova de Gaia
- Életkor
- 18 év and over
- People
- 140 worldwide
- Run by
- Zymeworks BC Inc.
See details and how to joinNCT07164313 - 3. fázisTaking peopleNeladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Where
- Cascais, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00 - 3. fázisTaking peopleA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Where
- Braga, Cascais, Coimbra, Lisbon, Loures, Porto, Senhora Da Hora
- Életkor
- 18 év and over
- People
- 830 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00 - 3. fázisTaking peopleClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Where
- Braga, Coimbra, Faro, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 780 worldwide
- Run by
- Summit Therapeutics
See details and how to joinNCT06767514 · EU 2024-518629-14-00 - 1. fázisNot yet taking people in PortugáliaA phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
- Where
- Porto
- Életkor
- 18 év and over
- People
- 62 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2025-521702-18-00 - 3. fázisTaking peoplePhase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)
- Where
- Braga, Lisbon, Porto, Senhora Da Hora
- Életkor
- 18 év and over
- People
- 168 worldwide
- Run by
- Amgen Inc.
See details and how to join2026-525489-23-00 - No phaseNot yet taking people in PortugáliaFamily-centred Pulmonary Rehabilitation to Empower Carers
- Where
- Aveiro, Figueira da Foz Municipality, Lisbon, Matosinhos Municipality, Santa Maria da Feira, Vila Nova de Gaia
- Életkor
- 18 év and over
- People
- 120
- Run by
- Aveiro University
See details and how to joinNCT07791147 - 3. fázisFut, nem toborozStudy Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
- Where
- Lisbon, Senhora Da Hora
- Életkor
- 18 év and over
- People
- 156 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-520050-38-00 - 3. fázisTaking peopleA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Where
- Coimbra, Guimaraes, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06203210 · EU 2023-509628-16-00 - 2. fázisBefejeződöttDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Lisbon, Matosinhos, Porto
- Életkor
- 18 év and over
- People
- 204 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00 - No phaseNot yet taking people in PortugáliaCLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS
- Where
- Lisbon
- Életkor
- 18 év and over
- People
- 140
- Run by
- Universidade Nova de Lisboa
See details and how to joinNCT07630246 - 2/3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Adult Participants with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Where
- Braga, Porto
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- AbbVie Deutschland GmbH & Co. KG
See details and how to join2024-518586-10-00 - 3. fázisNot yet taking people in PortugáliaA Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
- Where
- Braga, Faro, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Maia Biotechnology
See details and how to joinNCT06908304 · EU 2024-520164-33-00 - No phaseNot yet taking people in PortugáliaPrehabilitation for Lung Cancer Patients Undergoing Lung Resection
- Where
- Porto
- Életkor
- 18 év and over
- People
- 200
- Run by
- Universidade do Porto
See details and how to joinNCT06802627 - 1/2. fázisTaking peopleNeoadjuvant Immunotherapy with Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) followed by Radical Radiotherapy or Chemoradiotherapy – IDEAR
- Where
- Porto
- Életkor
- 18 év and over
- People
- 30
- Run by
- Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.
See details and how to join2024-518804-32-00